Objectives ACAT2 is the exclusive cholesterol-esterifying enzyme in hepatocytes and enterocytes. Hepatic ABCA1 transfers unesterified cholesterol (UC) to apoAI, thus generating HDL. By changing the hepatic UC pool available for ABCA1, ACAT2 may affect HDL metabolism. The aim of this study was to reveal whether hepatic ACAT2 influences HDL metabolism. Design WT and LXRα/β double knockout (DOKO) mice were fed a western-type diet for 8 weeks. Animals were i.p. injected with an antisense oligonucleotide targeted to hepatic ACAT2 (ASO6), or with an ASO control. Injections started 4 weeks after, or concomitantly with, the beginning of the diet. Results ASO6 reduced liver cholesteryl esters, while not inducing UC accumulation. ASO6 increased hepatic ABCA1 protein independently of the diet conditions. ASO6 affected HDL lipids (increased UC) only in DOKO, while it increased apoE-containing HDL in both genotypes. In WT mice ASO6 led to the appearance of large HDL enriched in apoAI and apoE. Conclusions The use of ASO6 revealed a new pathway by which the liver may contribute to HDL metabolism in mice. ACAT2 seems to be a hepatic player affecting the cholesterol fluxes fated to VLDL or to HDL, the latter via up-regulation of ABCA1.
References
[1]
Fazio S, Linton M (2006) Failure of ACAT inhibition to retard atherosclerosis. N Engl J Med 354: 1307–1309. doi: 10.1056/nejme068012
[2]
Pramfalk C, Eriksson M, Parini P (2012) Cholesteryl esters and ACAT. Eur J Lipid Sci Tech 114: 624–633. doi: 10.1002/ejlt.201100294
[3]
Rudel LL, Lee RG, Parini P (2005) ACAT2 is a target for treatment of coronary heart disease associated with hypercholesterolemia. Arterioscler Thromb Vasc Biol 25: 1112–1118. doi: 10.1161/01.atv.0000166548.65753.1e
[4]
Willner EL, Tow B, Buhman KK, Wilson M, Sanan DA, et al. (2003) Deficiency of acyl CoA:cholesterol acyltransferase 2 prevents atherosclerosis in apolipoprotein E-deficient mice. Proc Natl Acad Sci U S A 100: 1262–1267. doi: 10.1073/pnas.0336398100
[5]
Bell TA 3rd, Kelley K, Wilson MD, Sawyer JK, Rudel LL (2007) Dietary fat-induced alterations in atherosclerosis are abolished by ACAT2-deficiency in ApoB100 only, LDLr-/- mice. Arterioscler Thromb Vasc Biol 27: 1396–1402. doi: 10.1161/atvbaha.107.142802
[6]
Lee RG, Kelley KL, Sawyer JK, Farese RV Jr, Parks JS, et al. (2004) Plasma cholesteryl esters provided by lecithin:cholesterol acyltransferase and acyl-coenzyme a:cholesterol acyltransferase 2 have opposite atherosclerotic potential. Circ Res 95: 998–1004. doi: 10.1161/01.res.0000147558.15554.67
[7]
Ma J, Folsom AR, Lewis L, Eckfeldt JH (1997) Relation of plasma phospholipid and cholesterol ester fatty acid composition to carotid artery intima-media thickness: the Atherosclerosis Risk in Communities (ARIC) Study. The Am J Clin Nutr 65: 551–559.
[8]
Warensjo E, Sundstrom J, Vessby B, Cederholm T, Riserus U (2008) Markers of dietary fat quality and fatty acid desaturation as predictors of total and cardiovascular mortality: a population-based prospective study. Am J Clin Nutr 88: 203–209.
[9]
Miller CD, Thomas MJ, Hiestand B, Samuel MP, Wilson MD, et al. (2012) Cholesteryl esters associated with acyl-CoA:cholesterol acyltransferase predict coronary artery disease in patients with symptoms of acute coronary syndrome. Acad Emerg Med 19: 673–682. doi: 10.1111/j.1553-2712.2012.01378.x
[10]
Bell TA 3rd, Brown JM, Graham MJ, Lemonidis KM, Crooke RM, et al. (2006) Liver-specific inhibition of acyl-coenzyme a:cholesterol acyltransferase 2 with antisense oligonucleotides limits atherosclerosis development in apolipoprotein B100-only low-density lipoprotein receptor-/- mice. Arterioscler Thromb Vasc Biol 26: 1814–1820. doi: 10.1161/01.atv.0000225289.30767.06
[11]
Buhman KK, Accad M, Novak S, Choi RS, Wong JS, et al. (2000) Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice. Nat Med 6: 1341–1347.
[12]
Temel RE, Lee RG, Kelley KL, Davis MA, Shah R, et al. (2005) Intestinal cholesterol absorption is substantially reduced in mice deficient in both ABCA1 and ACAT2. J Lipid Res 46: 2423–2431. doi: 10.1194/jlr.m500232-jlr200
[13]
Brown JM, Bell TA 3rd, Alger HM, Sawyer JK, Smith TL, et al. (2008) Targeted depletion of hepatic ACAT2-driven cholesterol esterification reveals a non-biliary route for fecal neutral sterol loss. J Biol Chem 283: 10522–10534. doi: 10.1074/jbc.m707659200
[14]
Zhang J, Kelley KL, Marshall SM, Davis MA, Wilson MD, et al. (2012) Tissue-specific knockouts of ACAT2 reveal that intestinal depletion is sufficient to prevent diet-induced cholesterol accumulation in the liver and blood. J Lipid Res 53: 1144–1152. doi: 10.1194/jlr.m024356
[15]
Alberti S, Schuster G, Parini P, Feltkamp D, Diczfalusy U, et al. (2001) Hepatic cholesterol metabolism and resistance to dietary cholesterol in LXRbeta-deficient mice. J Clin Invest 107: 565–573. doi: 10.1172/jci9794
[16]
Carr TP, Parks JS, Rudel LL (1992) Hepatic ACAT activity in African green monkeys is highly correlated to plasma LDL cholesteryl ester enrichment and coronary artery atherosclerosis. Arterioscler Thromb 12: 1274–1283. doi: 10.1161/01.atv.12.11.1274
[17]
Lada AT, Davis M, Kent C, Chapman J, Tomoda H, et al. (2004) Identification of ACAT1- and ACAT2-specific inhibitors using a novel, cell-based fluorescence assay: individual ACAT uniqueness. J Lipid Res 45: 378–386. doi: 10.1194/jlr.d300037-jlr200
[18]
Parini P, Johansson L, Br？ijersén A, Angelin B, Rudling M (2006) Lipoprotein profiles in plasma and interstitial fluid analyzed with an automated gel-filtration system. Eur J Clin Invest 36: 98–104. doi: 10.1111/j.1365-2362.2006.01597.x
[19]
Carr TP, Andresen CJ, Rudel LL (1993) Enzymatic determination of triglyceride, free cholesterol, and total cholesterol in tissue lipid extracts. Clin Biochem 26: 39–42. doi: 10.1016/0009-9120(93)90015-x
[20]
Lovgren-Sandblom A, Heverin M, Larsson H, Lundstrom E, Wahren J, et al. (2007) Novel LC-MS/MS method for assay of 7alpha-hydroxy-4-cholesten-3-one in human plasma. Evidence for a significant extrahepatic metabolism. J Chromatogr B Analyt Technol Biomed Life Sci 856: 15–19. doi: 10.1016/j.jchromb.2007.05.019
[21]
Slatis K, Gafvels M, Kannisto K, Ovchinnikova O, Paulsson-Berne G, et al. (2010) Abolished synthesis of cholic acid reduces atherosclerotic development in apolipoprotein E knockout mice. J Lipid Res 51: 3289–3298. doi: 10.1194/jlr.m009308
[22]
Duong PT, Collins HL, Nickel M, Lund-Katz S, Rothblat GH, et al. (2006) Characterization of nascent HDL particles and microparticles formed by ABCA1-mediated efflux of cellular lipids to apoA-I. J Lipid Res 47: 832–843. doi: 10.1194/jlr.m500531-jlr200
[23]
Favari E, Lee M, Calabresi L, Franceschini G, Zimetti F, et al. (2004) Depletion of pre-beta-high density lipoprotein by human chymase impairs ATP-binding cassette transporter A1- but not scavenger receptor class B type I-mediated lipid efflux to high density lipoprotein. J Biol Chem 279: 9930–9936. doi: 10.1074/jbc.m312476200
[24]
Rothblat GH (1974) Cholesteryl ester metabolism in tissue culture cells. I. Accumulation in Fu5AH rat hepatoma cells. Lipids 9: 526–535. doi: 10.1007/bf02532500
[25]
Rothblat GH, Arbogast L, Kritchevsky D, Naftulin M (1976) Cholesteryl ester metabolism in tissue culture cells: II. Source of accumulated esterified cholesterol in Fu5AH rat hepatoma cells. Lipids 11: 97–108. doi: 10.1007/bf02532658
[26]
Zanotti I, Poti F, Pedrelli M, Favari E, Moleri E, et al. (2008) The LXR agonist T0901317 promotes the reverse cholesterol transport from macrophages by increasing plasma efflux potential. J Lipid Res 49: 954–960. doi: 10.1194/jlr.m700254-jlr200
[27]
de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, et al. (2010) The ability to promote efflux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol 30: 796–801. doi: 10.1161/atvbaha.109.199158
[28]
Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, et al. (2011) Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 364: 127–135. doi: 10.1056/nejmoa1001689
[29]
de la Llera-Moya M, Rothblat GH, Connelly MA, Kellner-Weibel G, Sakr SW, et al. (1999) Scavenger receptor BI (SR-BI) mediates free cholesterol flux independently of HDL tethering to the cell surface. J Lipid Res 40: 575–580.
[30]
Alger HM, Brown JM, Sawyer JK, Kelley KL, Shah R, et al. (2010) Inhibition of acyl-coenzyme A:cholesterol acyltransferase 2 (ACAT2) prevents dietary cholesterol-associated steatosis by enhancing hepatic triglyceride mobilization. J Biol Chem 285: 14267–14274. doi: 10.1074/jbc.m110.118422
[31]
Yancey PG, Bortnick AE, Kellner-Weibel G, de la Llera-Moya M, Phillips MC, et al. (2003) Importance of different pathways of cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 23: 712–719.
[32]
Favari E, Calabresi L, Adorni MP, Jessup W, Simonelli S, et al. (2009) Small discoidal pre-beta1 HDL particles are efficient acceptors of cell cholesterol via ABCA1 and ABCG1. Biochemistry 48: 11067–11074. doi: 10.1021/bi901564g
[33]
Pedrelli M, Davoodpour P, Degirolamo C, Gomaraschi M, Larsson L, et al. (2010) HDL Metabolism and Hepatic Acyl Coenzyme A: Cholesterol Acyltransferase (ACAT) 2 Inhibition in Mice. Arterioscler Thromb Vasc Biol 30: E183–E321. doi: 10.1016/s1567-5688(11)70176-3
[34]
Oram JF (2003) HDL apolipoproteins and ABCA1: partners in the removal of excess cellular cholesterol. Arterioscler Thromb Vasc Biol 23: 720–727. doi: 10.1161/01.atv.0000054662.44688.9a
[35]
Wang MD, Franklin V, Sundaram M, Kiss RS, Ho K, et al. (2007) Differential regulation of ATP binding cassette protein A1 expression and ApoA-I lipidation by Niemann-Pick type C1 in murine hepatocytes and macrophages. J Biol Chem 282: 22525–22533. doi: 10.1074/jbc.m700326200
[36]
Linder MD, Mayranpaa MI, Peranen J, Pietila TE, Pietiainen VM, et al. (2009) Rab8 regulates ABCA1 cell surface expression and facilitates cholesterol efflux in primary human macrophages. Arterioscler Thromb Vasc Biol 29: 883–888. doi: 10.1161/atvbaha.108.179481
[37]
Singaraja RR, Kang MH, Vaid K, Sanders SS, Vilas GL, et al. (2009) Palmitoylation of ATP-binding cassette transporter A1 is essential for its trafficking and function. Circ Res 105: 138–147. doi: 10.1161/circresaha.108.193011
[38]
Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, et al. (2005) Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J Clin Invest 115: 1333–1342. doi: 10.1172/jci23915
[39]
Camont L, Chapman MJ, Kontush A (2011) Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 17: 594–603. doi: 10.1016/j.molmed.2011.05.013
[40]
Tang W, Ma Y, Jia L, Ioannou YA, Davies JP, et al. (2008) Niemann-Pick C1-like 1 is required for an LXR agonist to raise plasma HDL cholesterol in mice. Arterioscler Thromb Vasc Biol 28: 448–454. doi: 10.1161/atvbaha.107.160465
[41]
Vaisman BL, Lambert G, Amar M, Joyce C, Ito T, et al. (2001) ABCA1 overexpression leads to hyperalphalipoproteinemia and increased biliary cholesterol excretion in transgenic mice. J Clin Invest 108: 303–309. doi: 10.1172/jci200112517
[42]
Temel RE, Tang W, Ma Y, Rudel LL, Willingham MC, et al. (2007) Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest 117: 1968–1978. doi: 10.1172/jci30060
[43]
Krimbou L, Denis M, Haidar B, Carrier M, Marcil M, et al. (2004) Molecular interactions between apoE and ABCA1: impact on apoE lipidation. J Lipid Res 45: 839–848. doi: 10.1194/jlr.m300418-jlr200
[44]
Zanotti I, Pedrelli M, Poti F, Stomeo G, Gomaraschi M, et al. (2011) Macrophage, but not systemic, apolipoprotein E is necessary for macrophage reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol 31: 74–80. doi: 10.1161/atvbaha.110.213892
[45]
Yancey PG, de la Llera-Moya M, Swarnakar S, Monzo P, Klein SM, et al. (2000) High density lipoprotein phospholipid composition is a major determinant of the bi-directional flux and net movement of cellular free cholesterol mediated by scavenger receptor BI. J Biol Chem 275: 36596–36604. doi: 10.1074/jbc.m006924200
[46]
Camont L, Lhomme M, Rached F, Le Goff W, Negre-Salvayre A, et al. (2013) Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol 33: 2715–2723. doi: 10.1161/atvbaha.113.301468
[47]
Lee RG, Shah R, Sawyer JK, Hamilton RL, Parks JS, et al. (2005) ACAT2 contributes cholesteryl esters to newly secreted VLDL, whereas LCAT adds cholesteryl ester to LDL in mice. J Lipid Res 46: 1205–1212. doi: 10.1194/jlr.m500018-jlr200
[48]
Parini P, Jiang ZY, Einarsson C, Eggertsen G, Zhang SD, et al. (2009) ACAT2 and human hepatic cholesterol metabolism: identification of important gender-related differences in normolipidemic, non-obese Chinese patients. Atherosclerosis 207: 266–271. doi: 10.1016/j.atherosclerosis.2009.04.010
[49]
Chen SN, Cilingiroglu M, Todd J, Lombardi R, Willerson JT, et al. (2009) Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. BMC Med Genet 10: 111. doi: 10.1186/1471-2350-10-111
[50]
Qiu S, Luo S, Evgrafov O, Li R, Schroth GP, et al. (2012) Single-neuron RNA-Seq: technical feasibility and reproducibility. Front Genet 3: 124. doi: 10.3389/fgene.2013.00023
[51]
Parini P, Davis M, Lada AT, Erickson SK, Wright TL, et al. (2004) ACAT2 is localized to hepatocytes and is the major cholesterol-esterifying enzyme in human liver. Circulation 110: 2017–2023. doi: 10.1161/01.cir.0000143163.76212.0b
[52]
Jiang ZY, Jiang CY, Wang L, Wang JC, Zhang SD, et al. (2009) Increased NPC1L1 and ACAT2 expression in the jejunal mucosa from Chinese gallstone patients. Biochem Biophys Res Commun 379: 49–54. doi: 10.1016/j.bbrc.2008.11.131
[53]
Jiao S, Cole TG, Kitchens RT, Pfleger B, Schonfeld G (1990) Genetic heterogeneity of lipoproteins in inbred strains of mice: analysis by gel-permeation chromatography. Metabolism 39: 155–160. doi: 10.1016/0026-0495(90)90069-o
[54]
Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL (1993) In vivo protection against endotoxin by plasma high density lipoprotein. Proceedings of the National Academy of Sciences of the United States of America 90: 12040–12044. doi: 10.1073/pnas.90.24.12040
[55]
Feingold KR, Grunfeld C (2011) The role of HDL in innate immunity. J Lipid Res 52: 1–3. doi: 10.1194/jlr.e012138
